An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

Inclusion Criteria: * Histologically or cytologically confirmed advanced/metastatic solid tumor and refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant * IO therapy resistant or insensitive tumors * Have at least 2 tumor lesions accessible for biopsy * Eastern Cooperative Oncology Group Performance Status of 0 or 1 Exclusion Criteria: * Primary CNS malignancy * Participants with other active malignancy requiring concurrent intervention * Uncontrolled or significant cardiovascular disease Other protocol-defined inclusion/exclusion criteria apply